# US 2026/0083757 A1 · Dosage Forms For Delivery Of Self-Emulsifying Drug Delivery Systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083757 A1
- Document ID: US20260083757A1
- Status: Published application
- Kind: A1
- Application number: 18/891,058
- Filed: 2024-09-20
- Published: 2026-03-26
- Earliest claimed: 2024-09-20
- Assignees: Fertin Pharma A/S
- Applicants: Fertin Pharma A/S
- Inventors: Sanne Skov Jensen; Gitte Nykjær Nikolajsen; Benjamin Bugge Wahlqvist
- Web page: https://patentgrep.com/patent/US20260083757A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A dosage form for delivery of cannabinoids includes a formulation including: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

## Claims

### Claim at position 1

1-115. (canceled)

### Claim 116

A liquid dosage form for delivery of cannabinoids comprising a formulation, the formulation comprising:
one or more self-emulsifying drug delivery systems (SEDDS) comprising one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and
one or more cannabinoids comprising one or more isolated or synthetic cannabinoids in an amount of at least 20% by weight of the formulation.

### Claim 117 (depends on 116)

The liquid dosage form according to claim 116, wherein the dynamic viscosity of the liquid dosage form at a temperature of 25 Degree Celsius is 10 to 100 mPa·s.

### Claim 118 (depends on 116)

The liquid dosage form according to claim 116, wherein the dynamic viscosity of the liquid dosage form at a temperature of 25 Degree Celsius is at least 50.0 mPa·s.

### Claim 119 (depends on 116)

The liquid dosage form according to claim 116, wherein the formulation is dispersed in an oil.

### Claim 120 (depends on 116)

The liquid dosage form according to claim 116, wherein the formulation is for direct peroral delivery.

### Claim 121 (depends on 116)

The liquid dosage form according to claim 116, wherein the absolute bioavailability of the one or more cannabinoids is at least 4.0%.

### Claim 122 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS is present in an amount of at least 40% by weight of the formulation.

### Claim 123 (depends on 116)

The liquid dosage form according to claim 116, wherein the formulation does not comprise sugar alcohol or sugars.

### Claim 124 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS and the one or more cannabinoids constitute at least 50% by weight of the formulation.

### Claim 125 (depends on 116)

The liquid dosage form according to claim 116, further comprising sesame oil, corn oil, and/or medium-chained triglycerides.

### Claim 126 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS is stable at a pH of about 1-4.

### Claim 127 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS is liquid.

### Claim 128 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS comprises one or more lipids.

### Claim 129 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS comprises one or more oils selected from the group consisting of almond oil, castor oil, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, rapeseed oil, safflower oil, sesame oil, soybean oil, sunflower oil, and combinations thereof.

### Claim 130 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS comprises one or more triglycerides selected from one or more C4 to C14 triglycerides.

### Claim 131 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS comprises one or more triglycerides comprising a fully hydrogenated vegetable oil.

### Claim 132 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS comprises one or more lipophilic compounds selected from the group consisting of glyceryl caprylate, glyceryl caprate, glyceryl monocaprylate, glyceryl monooleate, glyceryl monostearate, glyceryl monolinoleate, polyglyceryl-3 dioleate, propylene glycol dicaprylocaprate, propylene glycol dilaurate, benzyl alcohol, alpha-tocopherol, isopropyl myristate, glycerol monocaprylocaprate, and combinations thereof.

### Claim 133 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety is selected from the group consisting of sugar-lipid based surfactants with PEG modification, PEG containing polymer based surfactants, PEGylated emulsifiers, and combinations thereof.

### Claim 134 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety is sugar-lipid based surfactants with PEG modification selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan trioleate, and combinations thereof.

### Claim 135 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety is PEG containing polymer based surfactants selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, and combinations thereof.

### Claim 136 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety is PEGylated emulsifiers selected from the group consisting of d-alpha-tocopheryl polyethylene glycol succinate, d-alpha-tocopheryl PEG-1000 succinate, PEG-15 hydroxystearate, PEG-30 castor oil, PEG-32 lauroyl glycerides, PEG-32 stearoyl glycerides, PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-6 lauroyl glycerides, PEG-6 linoleoyl glycerides, PEG-6 oleoyl glycerides, PEG-8 caprylic/capric glycerides, polyoxyl 20 cetostearyl ether, polyoxyethylenue-laurylether, polyoxyethylene-23-laurylether, and combinations thereof.

### Claim 137 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more SEDDS further comprises one or more hydrophilic solvents in an amount of at least 5% by weight of the by weight of the one or more SEDDS.

### Claim 138 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants further comprises one or more surfactants having a chemical structure that does not include a polyethylene glycol (PEG) moiety.

### Claim 139 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants comprises one or more surfactants having a chemical structure that does not include a polyethylene glycol (PEG) moiety being selected from the group consisting of monoglycerides, sugar-lipid based surfactants, and combinations thereof.

### Claim 140 (depends on 116)

The liquid dosage form according to claim 116, wherein the one or more surfactants comprises one or more surfactants having a chemical structure that does not include a polyethylene glycol (PEG) moiety comprising polyglycerol esters of fatty acids.

### Claim 141

A solid dosage form for delivery of cannabinoids comprising a formulation, the formulation comprising:
one or more self-emulsifying drug delivery systems (SEDDS) comprising one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and
one or more cannabinoids comprising one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.
